

ASSEMBLY, No. 451

STATE OF NEW JERSEY

218th LEGISLATURE

PRE-FILED FOR INTRODUCTION IN THE 2018 SESSION

Sponsored by:

Assemblyman GARY S. SCHAER

District 36 (Bergen and Passaic)

Assemblyman TIM EUSTACE

District 38 (Bergen and Passaic)

Assemblyman DANIEL R. BENSON

District 14 (Mercer and Middlesex)

Co-Sponsored by:

Assemblywoman Murphy

SYNOPSIS

Creates Clinical Trials Working Group.

CURRENT VERSION OF TEXT

Introduced Pending Technical Review by Legislative Counsel.



(Sponsorship Updated As Of: 12/4/2018)

1 AN ACT creating a Clinical Trials Working Group.

2

3 **BE IT ENACTED** *by the Senate and General Assembly of the State*
4 *of New Jersey:*

5

6 1. The Legislature finds and declares that historically, while
7 New Jersey has been at the forefront of pharmaceutical research,
8 development and manufacturing, when it comes time in the
9 development of new drugs and pharmaceuticals to test them in a
10 clinical setting, the companies that have developed those products
11 have traditionally found it necessary to go out of State – to the
12 medical centers of New York City and Philadelphia in particular –
13 to run clinical trials. The Legislature further finds and declares
14 that, with the modern-day wealth of institutions of higher education
15 in the State, and the number of world class teaching and research
16 hospitals in the State, some of which are connected to those
17 institutions of higher education, more of those clinical trials should
18 be staying in-State, through the collaborative efforts of the
19 pharmaceutical manufacturers and the universities and hospitals
20 which operate here in New Jersey.

21

22 2. There is established a Clinical Trials Working Group,
23 hereinafter referred to as the “working group.”

24 a. The working group shall be comprised of 15 members, as
25 follows:

26 (1) four members from the higher education community, to
27 include one member from Rutgers, the State University of New
28 Jersey appointed by the President thereof, one member from Rowan
29 University appointed by the President thereof, one member from the
30 Rutgers Cancer Institute of New Jersey appointed by the director
31 thereof, and one member representing an independent institution of
32 higher education in New Jersey, to be appointed by the Governor;

33 (2) three members from New Jersey hospitals, to include one
34 member from the staff of University Hospital appointed by the
35 board of directors of the University Hospital, and two members to
36 be appointed by the Senate President upon the recommendation of
37 the New Jersey Hospital Association, one of whom shall represent a
38 hospital from the northern geographic region of the State and one of
39 whom shall represent a hospital from the southern geographic
40 region of the State;

41 (3) four members representing pharmaceutical manufacturing
42 companies in the State, which companies shall be members of the
43 HealthCare Institute of New Jersey, which shall make
44 recommendations as to these members. Of these four members, one
45 shall be appointed by the Governor, one shall be appointed by the
46 Speaker of the General Assembly, one shall be appointed by the
47 Minority Leader of the General Assembly, and one shall be
48 appointed by the Minority Leader of the Senate;

1 (4) two members representing biotech companies operating in
2 the State, which companies shall be members of BioNJ, which shall
3 make recommendations as to these members. One of these
4 members shall be appointed by the Speaker of the General
5 Assembly and one shall be appointed by the Minority Leader of the
6 Senate; and

7 (5) the Secretary of Higher Education and the Commissioner of
8 Health, who shall serve ex-officio.

9 Vacancies in the membership of the working group shall be filled
10 in the same manner as the original appointments were made.

11 b. The working group shall organize as soon as may be
12 practicable after the appointment of a majority of its members and
13 shall select a chairperson, from among the members representing
14 pharmaceutical manufacturing companies in the State.

15 c. The members shall serve without compensation but shall be
16 reimbursed for necessary expenses incurred in the performance of
17 their duties and within the limits of funds made available to the
18 working group.

19 d. The working group may meet and hold hearings at the places
20 it designates during the sessions or recesses of the Legislature.

21 e. The working group shall be entitled to call to its assistance
22 and avail itself of the services of the Office of Legislative Services,
23 as it may require.

24

25 3. It shall be the duty of the working group to: study the
26 reasons why historically, New Jersey's substantial pharmaceutical
27 industry in general and the many New Jersey based pharmaceutical
28 manufacturing companies in particular have had to look outside the
29 State to find appropriate clinical trials for the drugs and medications
30 they are developing and testing; identify any obstacles to
31 collaborations between the public and private sectors, the higher
32 education and health care communities, and the pharmaceutical
33 industry in attempting to undertake such collaborations; and to
34 make recommendations as to how the State, and its public and
35 private institutions of higher education and health care facilities can
36 be encouraged to collaborate in such endeavors and ways to
37 eliminate such obstacles and facilitate such endeavors.

38

39 4. The working group shall issue its report within six months of
40 its initial meeting. The report shall be submitted to the Governor,
41 and to the Legislature pursuant to section 2 of P.L.1991, c.164
42 (C.52:14-19.1). The report shall include the findings, conclusions
43 and recommendations of the working group for legislative or
44 administrative action, including, in particular, any recommendations
45 for legislation which would have, as its purpose, the undertaking of
46 more clinical trials within the State. The working group shall
47 expire on the 30th day after submitting its report.

1 5. This act shall take effect immediately.

2

3

4

STATEMENT

5

6 This bill creates the Clinical Trials Working Group to study why
7 historically, New Jersey's pharmaceutical industry has had to look
8 outside the State to find appropriate clinical trials for the drugs and
9 medications which it develops and tests.

10 The working group will be made up of public and private sector
11 representatives, some appointed from among the institutions and
12 organizations they represent, and others to be appointed by the
13 Governor or leadership of the Legislature.

14 In particular, the working group is charged with identifying
15 obstacles to collaborations between the public and private sectors,
16 the higher education and health care communities, and the
17 pharmaceutical industry in attempting to undertake such
18 collaborations; recommending ways in which the State, and its
19 public and private institutions higher education and health care
20 facilities, can be encouraged to collaborate in such endeavors; and
21 ways to eliminate such obstacles and facilitate such endeavors.

22 The working group shall issue its report within six months of its
23 initial meeting. The report shall be submitted to the Governor and
24 the Legislature and include the findings, conclusions and
25 recommendations of the working group for legislative or
26 administrative action, including, in particular, any recommendations
27 for legislation which would have, as its purpose, the undertaking of
28 more clinical trials within the State.